International and regional experts focus on RSV prevention at Pfizer MERA Maternal Immunization Summit
The summit highlighted the critical role of maternal vaccinations in the successful prevention of RSV and shed light on global best practices for such vaccination programs.
Dubai, UAE – More than 80 international and regional healthcare experts have convened at the Pfizer MERA Maternal Immunization Summit: Born Ready to discuss issues pertaining to maternal immunization. The summit, entitled 'RISE: Respiratory Immunization Summit for Excellence' and, held from 16-17 May 2025 in Cairo, Egypt, focused on the growing burden of neonatal respiratory syncytial virus (RSV) and the role of maternal vaccination in its successful prevention.
The summit aimed to increase awareness of the virus and its impact, in addition to the importance of maternal immunization in preventing RSV and protecting newborns. Experts addressed the challenges and barriers to the adoption of maternal immunization, shared best practices, and explored how healthcare providers can more effectively implement maternal immunization programs in the region.
Professor Irene Cetin, Professor of Obstetrics and Gynecology, University of Milan and Head of Obstetrics, Mangiagalli Policlinico Hospital Fondazione IRCCS Cà Granda, Milan, Italy, said: 'Maternal immunization leverages the natural pregnancy process whereby antibodies – disease-fighting molecules – pass naturally from mother to baby through the placenta, starting in the second trimester and peaking during the third. Maternal antibodies help protect infants at birth and during the first few months of life, before they are eligible to receive vaccinations themselves.'
The administration of a vaccine to an expectant mother activates the maternal immune system, triggering the production of immunoglobin G (IgG) antibodies, which pass through the placenta from the parental bloodstream.
Professor Mohamed Momtaz, Emeritus Professor of Obstetrics and Gynecology, Kasr Al Ainy Faculty of Medicine, Cairo University, Cairo, Egypt, said: 'Because of the way the placenta pumps antibodies into the fetus during the second and third trimesters of pregnancy, fetal IgG concentration usually exceeds the concentration of antibodies in the maternal circulation in full-term infants, meaning the baby is better protected from infectious diseases than the mother. This highlights the tremendous potential of maternal immunization to help prevent transmission of communicable diseases and reduce the impact of infections such as RSV. Furthermore, events like this summit encourage evidence-based conversations between healthcare providers and expectant mothers, while also highlighting practical approaches to communication and appropriate data sharing.'
According to the World Health Organization, RSV – a seasonal virus that leads to infections of the lungs and respiratory tract – is the most common cause of acute lower respiratory infections in children globally [i], responsible for an estimated 33 million such infections, more than three million hospitalizations and almost 60,000 deaths per year in children under 5 years of age [ii]. This trend is reflected regionally, where RSV infections are the leading cause of acute respiratory tract infections in young children, typically peaking during the winter months or the rainy season in humid countries.
Professor Hossam Al Tatari, Director of General Pediatrics and Pediatric Infectious Diseases Services at The Heart Medical Center, Al Ain, UAE said: 'RSV infection is very common, affecting almost all children within two years from birth. In adults and older, healthy children, RSV typically produces mild symptoms that mimic the common cold, but in the newborn babies below 6 months, and those otherwise immunocompromised, such as babies born prematurely, the infection can prove life-threatening. It is imperative that we explore every possible avenue to mitigate the risks associated with RSV, and take every step to prevent transmission, especially to the most vulnerable amongst us.'
Highlighting the benefits of maternal immunization to newborns and immunocompromised infants, Dr Hammam Haridy, Senior Director Regional Medical & Scientific Affairs at Pfizer MERA said: 'Infections such as RSV, while potentially dangerous, are preventable with vaccination. Despite the significant impact of RSV in the region and across the globe, comprehensive and consistent region-wide surveillance and burden data across the Middle East and North Africa region are currently limited. Forums such as the Maternal Immunization Summit are therefore crucial to drive buy-in of healthcare providers in order to increase awareness and tackle vaccine hesitancy. By providing a platform via which stakeholders can connect and share data and insights, we can drive the conversation around maternal vaccination, ensuring we make best use of available data in our interactions.'
Both the World Health Organization and the Strategic Group of Experts on Immunization recommend countries adopt measures to prevent severe RSV in infants [iii], with decisions on whether to use maternal immunization or monoclonal antibodies dependent upon a number of factors.
Emphasizing the need for collaboration between the medical community and vaccine developers to ensure maximum success in prevention, Merih Cetinkaya, Professor of Pediatrics, Health Sciences University and Head of Neonatology at Basaksehir Cam Sakura, City Hospital, Istanbul, Turkey, said: 'Communicable diseases such as RSV have considerable impact on neonatal health, affecting both our populations and our healthcare systems, and vaccinations remain a cornerstone in lessening this impact. As healthcare providers, we share responsibility with stakeholders across the healthcare landscape to understand such diseases, to leverage innovation and technology, and to ensure equitable access to life-saving vaccines, especially for the most vulnerable members of our communities.'
During the event, Pfizer underscored its ongoing commitment to shaping the future of public health through the power of vaccines. Over the years, Pfizer's vaccines have played a vital role in preventing, controlling, and in some cases nearly eradicating infectious diseases, safeguarding millions of lives around the world and across the MERA region. As a leader in biopharmaceutical innovation, the company remains deeply invested in research and development, driving forward new solutions with the aim of enhancing patient outcomes and advancing global health.
About Pfizer: Breakthroughs That Change Patients' Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety, and value in the discovery, development, and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments, and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
5 hours ago
- Zawya
Minister of Planning, Economic Development, and International Cooperation Discusses Opportunities for Joint Cooperation with the Rector of the United Nations University (UNU)
H.E. Dr. Rania Al-Mashat, Minister of Planning, Economic Development, and International Cooperation, met with Professor Tshilidzi Marwala, Rector of the United Nations University, to discuss opportunities for joint cooperation between the two sides. This was during the activities of the Tokyo International Conference on African Development (TICAD 9), in which Egypt is participating with a high-level delegation headed by H.E. Dr. Mostafa Madbouly, Prime Minister, on behalf of H.E. President Abdel Fattah El-Sisi, President of the Arab Republic of Egypt. During the meeting, the two sides explored avenues of collaboration within the framework of the pivotal role played by the United Nations University, established in 1975, in building bridges between academic institutions across continents and advancing scientific research to achieve sustainable development, particularly in the Global South. In this context, the Minister of Planning, Economic Development, and International Cooperation underscored the importance of the Tokyo International Conference on African Development, which paves the way for broader areas of cooperation and partnership between Japan and African countries, as well as regional and international organizations. Dr. Al-Mashat affirmed the government's keenness to strengthen partnerships and cooperation with United Nations organizations and international institutions in order to advance efforts to achieve sustainable development. At the same time, H.E. pointed to the national efforts to localise technology, develop a strategy for artificial intelligence and launch a national council for artificial intelligence in order to keep pace with developments in these technologies, which have become a necessary factor for achieving development in various fields. The Minister of Planning, Economic Development, and International Cooperation welcomed the prospect of cooperation and partnership with the United Nations University to build upon the strong and longstanding partnership between Egypt and the United Nations, as Egypt is a founding member of the UN system. For his part, Professor Tshilidzi Marwala, Rector of the United Nations University, emphasized the University's keenness to continuing and strengthening cooperation with the Egyptian government to support its efforts in the areas of digital transformation, artificial intelligence, human capital development, and other fields that contribute to the achievement of sustainable development. It is worth noting that Japan is one of Egypt's most significant Asian development partners. The cooperation portfolio currently includes about 18 development projects in support of the government's plan to achieve sustainable economic development goals. The cooperation portfolio between Egypt and Japan is in line with Egypt's Vision 2030, the government's action programme (2024-2027), and the priorities of Japanese funding policies. The total technical support and grants provided by Japan amounted to about $2.4 billion, in addition to development funds amounting to about $7.2 billion, in the fields of renewable energy, electricity, transport, civil aviation, antiquities, irrigation, education and health, and budget support. Distributed by APO Group on behalf of Ministry of Planning, Economic Development, and International Cooperation - Egypt.
Zawya
19 hours ago
- Zawya
Egypt, ADIB explore strategic partnership in digital healthcare, investment
Egypt Healthcare Authority held talks on Wednesday with Abu Dhabi Islamic Bank (ADIB) – Egypt to explore a strategic partnership in healthcare investment and digital transformation, the authority said in an official statement. The meeting, chaired by Ahmed El-Sobky, Chairperson of the Egypt Healthcare Authority and Supervisor of the Universal Health Insurance Project, brought together ADIB-Egypt CEO Mohamed Ali at the authority's headquarters in the New Administrative Capital. El-Sobky said the discussions focused on advancing Egypt's first 'virtual hospital' in Ismailia, alongside a national health data centre, artificial intelligence applications, and integrated e-health platforms. He emphasised that these projects reflect Egypt's vision to establish Africa's first virtual hospital and one of the largest digital healthcare facilities in the Middle East. The talks also addressed specialised financial training programmes for healthcare staff to enhance banking literacy, particularly in Upper Egypt, in line with national efforts to expand financial inclusion and promote digital banking. Both sides discussed facilitating salary disbursements for healthcare workers through on-site banking services, in addition to supporting young doctors under initiatives launched by the Central Bank of Egypt. El-Sobky announced that the authority will soon introduce a new public–private partnership (PPP) model aimed at attracting investment funds and banking capital, reinforcing its position as a leading healthcare provider in Egypt. He confirmed that a memorandum of understanding with ADIB-Egypt will be signed to establish a long-term strategic partnership. ADIB-Egypt CEO Mohamed Ali described the planned partnership as 'a significant step toward sustainable healthcare investment,' underscoring the bank's commitment to supporting Egypt's national projects and attracting foreign capital, particularly in the health sector. © 2025 Daily News Egypt. Provided by SyndiGate Media Inc. (
The National
a day ago
- The National
Warning over banking baby teeth 'to treat diabetes and autism'
Parents are banking stem cells from their children's milk teeth in the hope they can be used in the 'next frontier' for treating diabetes. Some companies even claim that the 'dental pulp' is already being used in treatments for debilitating and potentially life-threatening conditions, an investigation found. Dental pulp is the soft inner tissue found near the centre of a tooth which contains nerves, blood vessels and connective tissue. The investigation by the BMJ healthcare professionals' publication warned that companies may be misleading parents with 'outrageous claims' about how teeth can be used, saying claims about their future medical value are 'unproven and potentially misleading'. They also highlight current research using stem cells in multiple sclerosis, Parkinson's disease, and heart attacks. Experts were alarmed by claims that they could already treat autism and diabetes, which will now be reviewed by the UK's Advertising Standards Agency. Tooth stem cell banking costs around £1,900 ($2,560), with an additional annual storage fee of £95. Customers sign an agreement before being sent a collection kit when a child's tooth becomes wobbly. Lost teeth are then sent to a laboratory where the dental pulp is digested, stem cells cultured until a sufficient number are present, harvested then stored in liquid nitrogen. Three companies in the UK offering tooth stem cell banking – Future Health Biobank, BioEden and Stem Protect − all operate through one laboratory. Stem cells were first isolated from teeth in 2000, and less than a decade later companies began to offer tooth stem cell banking. These stem cells are 'especially valuable because they are younger and healthier,' Future Health Biobank says. Scientists have debated whether stem cells derived from dental pulp are comparable with those derived from bone marrow. Future Health Biobank says on its website that it has released 26 tooth stem cell samples for treatment − including for autism, type 1 diabetes and knee cartilage regeneration − all to private clinics in North America. It said it would review how information on its site is presented to ensure 'readers can clearly distinguish between client experiences and formally published clinical outcomes'. The company also says it has a 'robust, ongoing, storage stability validation programme' with quality control testing 'to ensure that there is no deterioration in the integrity, viability or future potential of biological samples'. The BioEden website says stem cell therapy has been described as the 'next frontier' for treating both type 1 and type 2 diabetes. It states it has 'already witnessed the remarkable evidence of these ongoing developments' among its own customers. One 28-year-old treated with dental cells has reported 'decreased swelling, an improvement in energy levels, and a reduction in their insulin application,' the website states. 'Another member, who's halfway through their treatment, has had similar results along with improvements in their liver function, and is to begin their second course later this year,' it continues. 'The best stem cells are young stem cells,' which is why it is 'advisable' to bank at the youngest age possible, it claims. Stem Protect cites cleft palate repair, sickle cell disease, HIV/AIDS, severe combined immunodeficiency, and knee cartilage repair under a section of its website headed, 'What treatments are tooth stem cells used for?' But several experts are concerned about the claims being made. Jill Shepherd, senior lecturer in stem cell biology at the University of Kent, says companies are selling the 'potential' for something that is not yet borne out by the science. 'There is a lack of evidence and a paucity of research using dental pulp stem cells to treat patients.' Sufyan Hussain, a clinician at King's College London who is an investigator on the UK arm of a global clinical trial evaluating stem cell therapy for type 1 diabetes, said work on dental pulp stem cells is at a very early pre-clinical stage. 'The stem cells being studied in clinical settings are predominantly from either donated embryos or sources readily available from adults. To my knowledge there is currently no active human clinical research using stem cells derived from baby teeth to treat diabetes. 'At present, there isn't a definitive answer regarding the optimal source of stem cells for future diabetes therapies.' Diabetes UK said more research was needed before it recommended people engage with commercial companies who are banking stem cells. Tim Nicholls, assistant director of policy, research and strategy at the National Autistic Society in the UK, said it was 'outrageous' that tooth stem cell procedures are being advertised to parents with the false claim of treating autism. 'Autism is not a disease or illness, it cannot be treated and there is no cure,' he said. 'It is dangerous and morally bankrupt to target potentially vulnerable people with expensive procedures that could, in fact, cause harm.' Experts are also concerned about the lack of independent information on tooth stem cell banking to help consumers make a fully informed choice, and say more oversight is needed of the information being used to promote the practice. Ms Shepherd also believes parents should be given more information on what type of tests are done to validate that stem cells are present in the stored samples, how they were collected and how long they can be viably stored. She also points out that the phrase 'stem cell' is being used as a catch-all. Websites list many pages of research, but these are unlikely to be from dental derived stem cells. 'It can be misleading. 'Such decisions can be emotive for parents. But there isn't the information out there to inform them, and the regulators should take an active role.' The BMJ findings were sent to the Advertising Standards Agency, which says it will review them.
